- Home
- GRNT vs DNA Comparison
GRNT vs DNA Comparison
Compare GRNT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- DNA
- Stock Information
- Founded
- GRNT 2013
- DNA 2008
- Country
- GRNT United States
- DNA United States
- Employees
- GRNT N/A
- DNA N/A
- Industry
- GRNT Blank Checks
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRNT Finance
- DNA Health Care
- Exchange
- GRNT Nasdaq
- DNA Nasdaq
- Market Cap
- GRNT 752.6M
- DNA 658.5M
- IPO Year
- GRNT N/A
- DNA N/A
- Fundamental
- Price
- GRNT $5.76
- DNA $10.24
- Analyst Decision
- GRNT Buy
- DNA Sell
- Analyst Count
- GRNT 2
- DNA 3
- Target Price
- GRNT $7.50
- DNA $9.67
- AVG Volume (30 Days)
- GRNT 997.5K
- DNA 1.6M
- Earning Date
- GRNT 08-07-2025
- DNA 08-07-2025
- Dividend Yield
- GRNT 7.61%
- DNA N/A
- EPS Growth
- GRNT N/A
- DNA N/A
- EPS
- GRNT 0.09
- DNA N/A
- Revenue
- GRNT $390,665,000.00
- DNA $237,417,000.00
- Revenue This Year
- GRNT $30.32
- DNA N/A
- Revenue Next Year
- GRNT $7.79
- DNA $15.91
- P/E Ratio
- GRNT $64.14
- DNA N/A
- Revenue Growth
- GRNT 6.26
- DNA 13.76
- 52 Week Low
- GRNT $4.52
- DNA $5.00
- 52 Week High
- GRNT $7.10
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- GRNT 39.46
- DNA 53.69
- Support Level
- GRNT $5.76
- DNA $8.21
- Resistance Level
- GRNT $6.72
- DNA $13.33
- Average True Range (ATR)
- GRNT 0.20
- DNA 0.92
- MACD
- GRNT -0.10
- DNA -0.04
- Stochastic Oscillator
- GRNT 0.52
- DNA 39.86
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.